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Introduction
Ž . Ž . Glucagon-like peptide-1 7-36 amide GLP-1 is Ž cleaved from proglucagon in mucosal endocrine cells L-. cells located predominately in the distal intestinal tract w x w x 6,8 , and in neurons of the brainstem 10 . In the periphery, GLP-1 has a regulatory role in glucose homeostasis by w x augmenting insulin release 12,15 , inhibiting gastric empw x tying 26 , and stimulating the activation of hepatic vagal w x afferent nerves 16 . While the role of GLP-1 in the CNS has not been as well studied, it has recently been shown that central infusion of exogenous GLP-1 reduces food w x intake in rats 22-24 . These findings raise the possibility that GLP-1 is involved with the homeostatic regulation of food intake, the process by which caloric intake and caloric expenditure are matched to keep parameters such as body adiposity within certain limits. In fact, several authors have suggested that central GLP-1 pathways are involved with the regulation of satiety, and have labelled w x GLP-1 a satiety factor 20,23 . Food intake can also be influenced by nonhomeostatic factors, such as the response to visceral illness. 'Visceral illness' is a term that encompasses the nausea andror anorexia that are symptomatic of a wide range of clinical conditions spanning ingestion of toxins, infectious disw x eases, and the effects of certain tumors or cancers 2,3,5,7 .
Ž . Lithium chloride LiCl is an emetic agent that produces aversive side-effects and symptoms associated with visceral illness, such as anorexia, vomiting in emetic species, 0006-8993r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved. 
Materials and methods

Animal preparation
Subjects were male Long-Evans rats weighing between 300 and 400 g at the onset of the experiments. They were individually housed in hanging stainless steel cages and maintained on a 12:12 h light:dark cycle. Laboratory rat Ž chow and water were provided ad libitum except where . Ž . noted . Under Equithesin 3.3 mlrkg; i.p. anesthesia, rats were implanted with 21-gauge stainless-steel cannulae Ž . Plastics One, Roanoke, VA aimed at the third ventricle. With bregma and lambda at the same vertical coordinate, the sagittal venous sinus was carefully displaced laterally with a metal probe, and the cannulae were placed directly on the midline, 2.2 mm posterior to bregma and 7.4 mm ventral to dura, and fixed to the skull with anchor screws and dental acrylic. The cannulae were fitted with removable obturators that extended 0.5 mm beyond the tip of the guide cannula. Each rat was given 0.15 ml each of Ž . Chloromycetin 100 mgrml; subcutaneously and Gentam-Ž . icin 40 mgrml; i.p. prophylactically. When rats regained Ž their preoperative body weights following surgery ap-. proximately 3 weeks , placement of i3vt cannulae were confirmed by administration of 10 ng angiotensin II in saline through the cannulae while the animals were water replete. Animals that did not drink at least 5 ml of water within 60 min were not used in the studies.
Experiment 1: effects of exendin on GLP-1-induced HIT cell insulin secretion and anorexia
To assess the effects of exendin on GLP-1 in vitro, HIT cells were first grown to confluence in KRB media over 3 days. Insulin secretion into the culture media was measured after 1 h of incubation with elevated glucose concentration and different combinations of peptides: Either 300 mg% glucose alone, 1.0 nM GLP-1 in 300 mg% glucose, w x 10 nM or 100 nM of exendin-9-39 added to 1.0 nM GLP-1 in 300 mg% glucose, or 10 nM or 100 nM of des His 1 Glu 9 exendin-4 added to 1.0 nM GLP-1 in 300 mg% glucose. Groups of 4 to 8 separate culture dishes were used for each condition.
To assess the effects of dHGex-4 on GLP-1-induced anorexia, rats were weighed and their food hoppers were removed from the cages 2 h before the beginning of the Ž . dark phase 1800 h . Rats were assigned to groups matched for body weight. Approximately 1 h before the beginning of the dark phase, rats were pretreated with an i3vt infu-Ž sion for all i3vt infusions reported, a 2.5 ml volume was manually infused with a Hamilton syringe over 60 s; see w x . Ž . Ref. 24 for details of either synthetic-CSF s-CSF or Ž . dHGex-4 10.0 mg; dissolved in s-CSF . Ten min later, rats were treated with a second i3vt infusion of either Ž . s-CSF or GLP-1 10.0 mg . This study consisted of the following groups that are identified by pretreatmentrtreat-Ž . ment infusions: Group s-CSFrGLP-1 CrG; n s 5 , Group Ž . dHGex-4rGLP-1 ErG; n s 5 , Group s-CSFrs-CSF Ž . Ž . CrC; n s 5 , and Group dHGex-4rs-CSF ErC; n s 5 . At the onset of the dark phase, food hoppers were weighed and returned to the rats cages; they were weighed again 4 h later. Table 1 Insulin secretion in HIT cell cultures 
Experiment 2: effects of dHGex-4 on drug-induced cFLI
To reduce stress-induced c-Fos expression on the test day, rats were regularly handled during recovery from surgery. Rats were pretreated with an i3vt infusion of Ž . either dHGex-4 10.0 mg or s-CSF, and 10 min later they were treated with either a second i3vt infusion of GLP-1 Ž . Ž 10.0 mg or an i.p. injection of either LiCl 76 mgrkg of a 0.15 M solution; this dose of LiCl produces CTA after a w x. Ž single conditioning episode 21 or isotonic saline 10 mlrkg; this dose produced volumes equal to LiCl injec-. tions . To accommodate perfusion and brain removal pro-Ž . cedures see below , rats were treated at a rate of one Ž every 15 min order counterbalanced between treatment . conditions between 1000 h and 1600 h on the test day. This study consisted of the following groups that are identified by pretreatmentrtreatment drug administration: Ž . Group s-CSFrGLP-1 CrG; n s 4 , Group dHGex-Ž . Ž . 4rGLP-1 ErG; n s 4 , Group s-CSFrLiCl CrL; n s 5 , Ž . group dHGex-4rLiCl ErL; n s 5 , and Group s-Ž . CSFrsaline CrS; n s 4 . Ž . Fig. 1 . Mean "S.E.M. 4-h food intake following i3vt infusions. Group CrG was pretreated with infusion of s-CSF followed by infusion of GLP-1, Group ErG was pretreated with infusion of dHGex-4 followed by infusion of GLP-1, Group CrC was given two successive infusions of s-CSF, and Group ErC was given pretreatment with dHGex-4 followed by infusion of s-CSF. ) P -0.05 relative to all other groups.
Two Ž . postrema A , the nucleus of the solitary tract B , and the lateral Ž . parabrachial nucleus C following i3vt infusions. Group CrG was pretreated with infusion of c-CSF followed by infusion of GLP-1; Group ErG was pretreated with infusion of dHGex-4 followed by infusion of GLP-1; Group CrL was pretreated with infusion of s-CSF followed by i.p. injection of LiCl; Group ErL was pretreated with infusion of dHGex-4 followed by injection of LiCl; and Group CrS was pretreated with infusion of s-CSF followed by injection of isotonic saline. ) P -0.05 relative to s-CSF pretreated groups. Ž . slices were rinsed 10 = , PBS and processed using the Ž . ABC method Vector Laboratories, Burlingame, CA . Slices were transferred to biotinylated goat antirabbit anti-Ž . body for 1 h, rinsed 6 = , PBS , transferred to avidin-bio-Ž tinylated peroxidase for 1 h, rinsed 3 = in PBS, 3 = in . PB , and developed with diaminobenzidine substrate inten-Ž . sified with nickel sulfate 6 min . Slices were rinsed Ž . 10 = , PBS , mounted on slides, and cover-slipped with Permount. Camera lucida drawings of c-Fos positive brain structures were prepared by an experimenter naive to group treatments. Care was taken so that each structure Ž was scored in approximately the same plane one section . per subject . Drawings were scored by two blinded raters who recorded the number and location of c-Fos positive nuclei. Scores across raters were averaged for statistical analyses.
Data analyses
Data from each study were analyzed using analyses of Ž . variance ANOVA . In Experiment 1, 4-h food intake data ( )Ž were analyzed using a two-way, 2 = 2 Pretreatment= . Treatment ANOVA. A one-way ANOVA was run to analyze data from the HIT cell portion of Experiment 1 Ž . using insulin secretion mUrml as the dependent measure. Because all groups needed to complete a two-way factorial design were not run in Experiment 2, one-way ANOVAs were run instead to compare groups using cFLI as the dependent measure. Separate ANOVAs were run to analyze cFLI data collected from each brain region. When significant differences were found, post hoc analyses were Ž . conducted using t-tests. In all cases, P -0.05 two-tailed indicated statistical significance.
Results
Experiment 1: effects of exendin on GLP-1-induced HIT cell insulin secretion and anorexia
Ž
. Average insulin secretion "S.E.M. assessed from HIT cell cultures in each of the treatment conditions are presented in Table 1 Data illustrating 4-h food intake following i3vt infusions are presented in Fig. 1 . Relative to Group CrC, rats pretreated with s-CSF followed by infusion of GLP-1 Ž . Group CrG had a significant reduction in 4-h food intake, thus providing evidence of GLP-1-induced anorexia. Pretreatment with dHGex-4 attenuated the ability of GLP-1 to reduce food intake, as intake of Group ErG did not differ significantly from that of the control group. Importantly, Group ErG ate significantly more food over 4 h than Group CrG. Finally, because Groups CrC and ErC did not differ reliably, the inference is that dHGex-4 alone did not modulate food intake. ANOVA performed on the data revealed a significant interaction between the pretreatw Ž . x ment and treatment effects F 1,16 s 4.77 . Post hoc tests revealed that while the pretreatment condition significantly influenced food intake between groups treated with GLP-1 Ž . i.e., Groups CrG vs. ErG , the pretreatment condition Ž had no influence on rats treated with s-CSF i.e., Groups . CrC vs. ErC .
Experiment 2: effects of dHGex-4 on drug-induced cFLI
Means nuclei positive for cFLI in the AP, the NTS, and the PBN are depicted in Fig. 2 , and representative photomicrographs through the NTS are presented in Fig. 3 . The groups pretreated with i3vt infusion of s-CSF and then Ž . treated with either i3vt infusion of GLP-1 Group CrG or Ž . i.p. injection of LiCl Group CrL had significantly more Ž . cFLI cells than the control group CrS ; this was the case Ž . Ž . Ž in the AP Fig. 2A , the NTS Fig. 2B , and the PBN Fig. . 2C . However, relative to groups pretreated with s-CSF, those that were given i3vt infusion of dHGex-4 and then Ž . either i3vt infusion of GLP-1 Group ErG or i.p. injec-Ž . tion of LiCl Group ErL had significant attenuation of drug-induced cFLI. Again, this was the case in each brain region in which cFLI was assessed. Finally, in both the AP and the NTS, cFLI levels in dHGex-4 pretreated groups did not differ reliably from the c-Fos expression that was Ž . observed in the control group CrS . However, while dHGex-4 attenuated cFLI in the PBN of LiCl treated Ž . animals Group ErL , this group did have greater levels of cFLI in the PBN when compared to Group CrS; Groups ErG and CrS also did not differ reliably. ANOVAs w Ž . performed on cFLI data collected from the AP F 4,17 s x w Ž . x w Ž . 12.20 , the NTS F 4,17 s 12.51 , and the PBN F 4,17 x s 15.72 each attained significance. Furthermore, post hoc tests confirmed all conclusions discussed above.
Discussion
Central infusion of GLP-1 and peripheral administration of LiCl have been observed to produce similar effects, w x including similar patterns of cFLI in the rat brain 21,24 . The similar actions produced by these drugs led us to assess the hypothesis that the neuronal activation caused by peripheral injection of LiCl is mediated by central GLP-1 receptor signalling. Consistent with our hypothesis, results from Experiment 2 revealed that pretreatment with i3vt infusion of the GLP-1 receptor antagonist, des His 1 Glu 9 exendin-4, attenuated LiCl-induced cFLI in several brainstem regions. Thus, LiCl-induced cFLI in the brainstem is mediated, in part, by GLP-1 receptor signalling. Importantly, while i3vt infusion of the antagonist also blocked cFLI in the brainstem produced by i3vt infusion of Ž . GLP-1 Experiment 2 , this antagonist did not produce any independent effects on c-Fos expression or food intake. Furthermore, the results of Experiment 2 replicate the observation that i3vt infusion of GLP-1, and i.p. injection of LiCl, produce robust cFLI in several brainstem regions, w x including the NTS, the AP, and the PBN 21,24 .
In Experiment 1, we provided the first in vivo demonstration that central infusion of the GLP-1 receptor antagonist, des His 1 Glu 9 exendin-4, blocks the ability of cen-Ž . trally infused GLP-1 to reduce short-term 4-h food intake. Furthermore, because 10.0 mg of the antagonist completely blocked the ability of 10.0 mg of GLP-1 to produce anorexia, this antagonist is effective when administered in a 1:1 ratio with GLP-1. Thus, des His  1 Glu   9 exendin-4 appears to be a more potent GLP-1 receptor ( )w x w x antagonist than exendin-9-39 , since exendin-9-39 must be administered in a concentration ten times stronger than w x GLP-1 in order to block GLP-1-induced anorexia 23 . The results from the HIT cell study confirm this greater potency of des His 1 Glu 9 exendin-4; only 10 nM of this antagonist were needed to completely inhibit insulin re-Ž . lease caused by GLP-1 1.0 nM , while a much larger w x Ž . concentration of exendin-9-39 100 nM was needed to block fully the actions of GLP-1.
While the present evidence suggests that GLP-1-receptor signalling is involved with LiCl-induced neuronal activation in the brainstem, it is unclear what physiological actions associated with LiCl administration may be mediated by these central GLP-1 pathways. Because LiCl is an emetic agent that produces aversive side-effects, such as vomiting and CTA, one possibility is that GLP-1 is a fundamental and key mediator of the aversive symptoms caused by LiCl administration. If so, then the anorexia and other effects caused by GLP-1 could be the result of aversive side-effects. This is consistent with the recent report that every dose of GLP-1 that reduced 4-h food intake was also capable of supporting a conditioned taste Ž aversion when administered via i3vt infusion to rats in w x w x. Ref. 25 ; but see Ref. 20 . Furthermore, if GLP-1 pathways are involved with LiCl-induced CTA andror anorexia, then pretreatment with the GLP-1 receptor antagonist should attenuate or even block these actions of LiCl. Although we are presently addressing these issues in our laboratory, preliminary data suggested that the GLP-1 receptor antagonist may weaken LiCl-induced taste aversions.
Importantly, however, it must be recalled that administration of LiCl produces a range of effects that are also associated with physiological systems involved with home-Ž ostatic regulation of food intake e.g., inhibition of gastric w x. emptying and anorexia; 1,5 and which are not necessarily aversive in nature. Thus, a second possibility is that GLP-1 pathways mediate physiological actions involved with both systems of homeostatic regulation of food intake and with systems underlying physiologically aversive states Ž . e.g., visceral illness .
GLP-1 may play a role in several physiological functions, with distinct anatomical loci within the brain where the peptide is released. Consistent with this, administration of GLP-1 directly into the PVN reduces food intake withw x out producing a CTA 13 . While seemingly at odds with our previous observation that GLP-1 infused into the third ventricle produces CTAs at all doses that reduce food w x intake 25 , peptides that are infused into the third ventricle interact with many brain areas including those near the w x fourth ventricle 11 . Hence, GLP-1-receptor signalling in the PVN may be critical for reducing food intake, while Ž GLP-1-receptor signalling in the brainstem e.g., in the . NTS my be critical for producing responses associated with aversive states. Further experiments will be required to sort out these possibilities.
Additional research is needed to verify what actions associated with LiCl administration are mediated by GLP-1 pathways. However, the present results may have important clinical implications.
Although not yet conclusively established, GLP-1-receptor signalling may be critical for mediating at least some aspects of the visceral illness associated with LiCl administration. Thus, GLP-1 pathways may also be involved with common human manifestations of visceral illness, including the wasting and debility seen in patients suffering from cancer and AIDS, and their associated chemotherapy treatments. Hence, GLP-1 receptor antagonists may be useful for reversing some or all of these symptoms by increasing appetite andror reducing the anorexia, nausea, and visceral illness occurring in a broad spectrum of clinical and pathologic conditions.
